Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system

[1]  M. Sarangdhar,et al.  Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study , 2022, Cancers.

[2]  M. Sarangdhar,et al.  Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study , 2022, Frontiers in Pharmacology.

[3]  K. Fairman,et al.  Fractured Timelines: Reporting Patterns for Bisphosphonate-Associated Atypical Fractures and Implications for Postmarket Surveillance. , 2022, The Senior care pharmacist.

[4]  J. Wallach,et al.  Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study , 2022, BMJ.

[5]  S. Reichenbach,et al.  Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study , 2022, JBMR plus.

[6]  Jingyi Li,et al.  Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries , 2022, Scientific Reports.

[7]  Y. Shimada,et al.  Successful Treatment of Atypical Femoral Fracture with Bowed Femur Using Contralateral Intramedullary Nail Combined with Early Daily Teriparatide. , 2022, Acta medica Okayama.

[8]  S. Zhao,et al.  Denosumab and risk of community-acquired pneumonia: A population-based cohort study. , 2022, The Journal of clinical endocrinology and metabolism.

[9]  E. Billington,et al.  Drug therapy for osteoporosis in older adults , 2022, The Lancet.

[10]  A. Khan,et al.  A Standardized Dataset of a Spontaneous Adverse Event Reporting System , 2022, Healthcare.

[11]  T. Howe,et al.  Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report , 2022, Calcified Tissue International.

[12]  Jennifer E Liu,et al.  Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. , 2021, Journal of the American College of Cardiology.

[13]  P. Jedlowski,et al.  DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020 , 2021, American Journal of Clinical Dermatology.

[14]  Hideaki Takahashi,et al.  Disturbance of osteonal bone remodeling and high tensile stresses on the lateral cortex in atypical femoral fracture after long-term treatment with Risedronate and Alfacalcidol for osteoporosis , 2021, Bone reports.

[15]  M. Bouxsein,et al.  Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long‐Term Odanacatib Fracture Trial , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  A. Avogaro,et al.  SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system , 2021, Cardiovascular Diabetology.

[17]  T. Martin,et al.  Physiological and Pharmacological Roles of PTH and PTHrP in Bone using their Shared Receptor, PTH1R. , 2021, Endocrine reviews.

[18]  T. Buclin,et al.  Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  J. Kane,et al.  Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System , 2020, Psychotherapy and Psychosomatics.

[20]  Erik J. Geiger,et al.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. , 2020, The New England journal of medicine.

[21]  D. Solomon,et al.  Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis , 2020, Annals of Internal Medicine.

[22]  C. Shore-Lorenti,et al.  Asian ethnicity is associated with atypical femur fractures in an Australian population study. , 2020, Bone.

[23]  L. Hornung,et al.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy , 2019, Osteoporosis International.

[24]  Shusen Sun,et al.  Assessing fluoroquinolone‐associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system , 2019, International journal of clinical practice.

[25]  R. Eastell,et al.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.

[26]  M. Bouxsein,et al.  Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. , 2019, Endocrine reviews.

[27]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[28]  T. Yamashita,et al.  The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration , 2018, Osteoporosis International.

[29]  E. Shane,et al.  Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures , 2018, Current Osteoporosis Reports.

[30]  R. Adler.  MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. , 2018, European journal of endocrinology.

[31]  Jacques P. Brown,et al.  Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  I. Tarkin,et al.  Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur , 2018, Osteoporosis International.

[33]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[34]  D. Bauer,et al.  Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Jacques P. Brown.  Antiresorptives: Safety Concerns—Clinical Perspective , 2017, Toxicologic pathology.

[36]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[37]  Jacques P. Brown,et al.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. , 2017, The lancet. Diabetes & endocrinology.

[38]  W. D. Kealey,et al.  The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer , 2017, BMJ Case Reports.

[39]  F. Grodstein,et al.  Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project , 2017, Journal of internal medicine.

[40]  R. Cantu,et al.  Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab , 2017, Acta orthopaedica.

[41]  Y. Ishibashi,et al.  Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis , 2016, Breast Cancer.

[42]  Yihe Hu,et al.  Prevalence of osteoporosis in China: a meta-analysis and systematic review , 2016, BMC Public Health.

[43]  A. Cheung,et al.  Unusual Femur Stress Fractures in Children With Osteogenesis Imperfecta and Intramedullary Rods on Long-term Intravenous Pamidronate Therapy , 2016, Journal of pediatric orthopedics.

[44]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[45]  G. Hortobagyi,et al.  Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  R. Eastell,et al.  Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study , 2016, British Medical Journal.

[47]  B. Ettinger,et al.  The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. , 2016, Bone.

[48]  Marc Boyer,et al.  Use of data mining at the Food and Drug Administration , 2016, J. Am. Medical Informatics Assoc..

[49]  J. Minguell,et al.  Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review , 2016, Osteoporosis International.

[50]  D. Bauer,et al.  Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  Smita Jha,et al.  Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological Analysis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  G. Im,et al.  Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review , 2015, Journal of bone metabolism.

[53]  Hang Lee,et al.  Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial , 2015, The Lancet.

[54]  K. Michaëlsson,et al.  Risk of atypical femoral fracture during and after bisphosphonate use , 2015, Acta orthopaedica.

[55]  G. Heyburn,et al.  Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. , 2014, Bone.

[56]  E. Drampalos,et al.  Atypical femoral fractures bilaterally in a patient receiving denosumab , 2014, Acta orthopaedica.

[57]  J. Schilcher,et al.  Atypical fracture of the femur in a patient using denosumab – a case report , 2014, Acta orthopaedica.

[58]  S. Belknap,et al.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. , 2013, The Journal of bone and joint surgery. American volume.

[59]  J. Cauley,et al.  Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. , 2013, The Journal of clinical endocrinology and metabolism.

[60]  Fahad M. Alshahrani,et al.  Femoral fractures in osteoporotic patients on bisphosphonates. A case report. , 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[61]  T. Perneger,et al.  Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. , 2012, Archives of internal medicine.

[62]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  T. Brown,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research , 2011 .

[64]  M. Hameed,et al.  Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. , 2011, The Journal of bone and joint surgery. American volume.

[65]  K. Michaëlsson,et al.  Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.

[66]  D. Black,et al.  Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. , 2011, The Journal of clinical endocrinology and metabolism.

[67]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[68]  M. Seibel,et al.  Atypical femoral fractures and bisphosphonate use. , 2010, The New England journal of medicine.

[69]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[70]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  N. Napoli,et al.  Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. , 2006, The New England journal of medicine.

[72]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[73]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[74]  Harry K. Genant,et al.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.

[75]  M. E. Tena-Sanabria,et al.  Atypical femoral fracture, case report and literature review. , 2019, Acta ortopedica mexicana.

[76]  R. Visvanathan,et al.  Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review , 2015, The journal of nutrition, health & aging.

[77]  P. Tugwell,et al.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.